We are pleased to invite investors and analysts to participate in our virtual event on Friday, 19 March, 2021, highlighting Roche data presented during the 2021 Muscular Dystrophy Association - MDA -Virtual Clinical and Scientific Conference, from 15th to 18th March.
14:00 – 15:00 CET / 13:00 - 14:00 GMT
9:00 – 10:00 am EDT / 6:00 – 7:00 am PDT
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 1pm CET on the day of the event. > click here
Agenda:
- Phase II/III SUNFISH part 2: 24-month efficacy and safety of risdiplam in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy
Paulo Fontoura, M.D. Ph.D., Global Head Neuroscience and Rare Diseases Clinical Development - Roche Neuroscience and Rare Disease franchise update
Simona Skerjanec, Therapeutic Area Head Neuroscience and Rare Diseases, Global Product Strategy - Q&A
Karl Mahler, Head of Investor Relations and Roche Group Planning
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.
A replay of the event will be available via > ir.roche.com
*privacy notice
|
